Christine Rojas

University of Maryland, Baltimore — United States

Medicine · Health Sciences

11h-index622citations67works1.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(12), Chronic Myeloid Leukemia Treatments(12), Multiple Myeloma Research and Treatments(11), Ovarian cancer diagnosis and treatment(9), Acute Lymphoblastic Leukemia research(8)

Publications67 total

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study
Blood·2025Open Access
Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry
Blood·2025
Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry
Blood·2025
Application of preclinical absorption, distribution, metabolism, elimination in vitro techniques for the characterization and compound library optimization of novel antibiotic gallium salophen
Drug Metabolism and Disposition·2025· 1 citedOpen Access
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
Cancer Reports·2024Open Access
Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors
Gynecologic Oncology·2024· 2 citedOpen Access
Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling
Clinical Proteomics·2024· 5 citedOpen Access
Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry
Blood·2023
Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America
Blood·2023· 2 citedOpen Access
POSTER: CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
Clinical Lymphoma Myeloma & Leukemia·2023
P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB
HemaSphere·2023Open Access
PB1852: COMPARISON OF CLINICAL CHARACTERISTICS OF ADULT CHILEAN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), ACCORDING TO THEIR HEALTH CARE SYSTEM: ANALYSIS WITHIN THE FRAMEWORK OF THE PTHEMA AML REGISTRY
HemaSphere·2023Open Access
P21 Survival disparities between Non-Hispanic Blacks and Whites with cervical cancer are largely dominated by adenocarcinoma histology and explained by modifiable factors
Gynecologic Oncology·2023
Additional file 2 of Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
Figshare·2023Open Access
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
Journal of Translational Medicine·2022· 19 citedOpen Access
Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma
Blood·2022· 1 cited
Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
Blood·2022· 1 cited
page 1 of 4Next →

Frequent Co-authors

Camila Peña(18), Nicholas W. Bateman(12), Thomas P. Conrads(12), Pilar León(11), Yovanni Casablanca(10), Kelly A. Conrads(9), Brian L. Hood(9), G. Larry Maxwell(9), Henry Idrobo(9), Kathleen M. Darcy(8), Hernán López‐Vidal(8), Virginia Abello(8), Jörge E. Cortes(7), Beatriz Moiraghi(7), Carolina Pavlovsky(7), Charles Chuah(7), Jeffrey H. Lipton(7), Philippe Rousselot(7), Gianantonio Rosti(7), Anna Turkina(7)